Tularaemia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tularaemia – Pipeline Review, H2 2016’, provides an overview of the Tularaemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tularaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Tularaemia

The report reviews pipeline therapeutics for Tularaemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Tularaemia therapeutics and enlists all their major and minor projects

The report assesses Tularaemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Tularaemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Tularaemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tularaemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aradigm Corp

Arno Therapeutics Inc

DynPort Vaccine Company LLC

Emergent BioSolutions Inc

EpiVax Inc

Grifols SA

Merck & Co Inc

Tetraphase Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Tularaemia Overview 7

Therapeutics Development 8

Pipeline Products for Tularaemia - Overview 8

Pipeline Products for Tularaemia - Comparative Analysis 9

Tularaemia - Therapeutics under Development by Companies 10

Tularaemia - Therapeutics under Investigation by Universities/Institutes 11

Tularaemia - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Tularaemia - Products under Development by Companies 14

Tularaemia - Products under Investigation by Universities/Institutes 15

Tularaemia - Companies Involved in Therapeutics Development 16

Aradigm Corp 16

Arno Therapeutics Inc 17

DynPort Vaccine Company LLC 18

Emergent BioSolutions Inc 19

EpiVax Inc 20

Grifols SA 21

Merck & Co Inc 22

Tetraphase Pharmaceuticals Inc 23

Tularaemia - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AR-12 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ARD-3100 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ARD-3150 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ciprofloxacin hydrochloride - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

EV-035 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecules for Infectious Diseases - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

solithromycin - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

SRI-011225 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

TP-271 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

tularaemia [strain A] vaccine - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

tularaemia [strain B] vaccine - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

tularaemia vaccine - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

tularemia vaccine - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Tularaemia - Dormant Projects 69

Tularaemia - Discontinued Products 70

Tularaemia - Product Development Milestones 71

Featured News & Press Releases 71

Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 71

May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 72

Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 72

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Tables

List of Tables

Number of Products under Development for Tularaemia, H2 2016 8

Number of Products under Development for Tularaemia – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Tularaemia – Pipeline by Aradigm Corp, H2 2016 16

Tularaemia – Pipeline by Arno Therapeutics Inc, H2 2016 17

Tularaemia – Pipeline by DynPort Vaccine Company LLC, H2 2016 18

Tularaemia – Pipeline by Emergent BioSolutions Inc, H2 2016 19

Tularaemia – Pipeline by EpiVax Inc, H2 2016 20

Tularaemia – Pipeline by Grifols SA, H2 2016 21

Tularaemia – Pipeline by Merck & Co Inc, H2 2016 22

Tularaemia – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Tularaemia – Dormant Projects, H2 2016 69

Tularaemia – Discontinued Products, H2 2016 70

List of Figures

List of Figures

Number of Products under Development for Tularaemia, H2 2016 8

Number of Products under Development for Tularaemia – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Top 10 Targets, H2 2016 25

Number of Products by Stage and Top 10 Targets, H2 2016 25

Number of Products by Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports